The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice

Endocrinology

Volumn 148, Issue 9, 2007, Pages 4466-4474

  Johnston, Sara ^a   Andrews, Sharon ^a   Shen, Victor ^b   Cosman, Felicia ^a,c   Lindsay, Robert ^a,c   Dempster, David W ^a,c   Iida Klein, Akiko ^a,c  

^a HELEN HAYES HOSPITAL   (United States)

^b MDS Inc   (Canada)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; C57BL 6 MOUSE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; LUMBAR VERTEBRA; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VERTEBRA BODY;

ALENDRONATE; ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; LUMBAR VERTEBRAE; MICE; MICE, INBRED C57BL; TERIPARATIDE;

EID: 34548089429     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0229     Document Type: Article

References (46)

1. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
3. Martin TJ, Seeman E 2007 New mechanisms and targets in the treatment of bone fragility. Clin Sci (Lond) 112:77-91
4. Rogers MJ 2003 New insights into the molecular mechanisms of actions of bisphosphonates. Curr Pharm Des 9:2643-2658
5. Porras AG, Holland SD, Gertz BJ 1999 Pharmacokinetics of alendronate. Clin Pharmacokinet 36:316-328
6. Chapurlat RD, Delmas PD 2006 Drug insights: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2:211-219
7. Fisher JE, Rodan GA, Reszka AA 2000 In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796
8. Kim YH, Kim G-S, Baek J-H 2002 Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34:145-151
9. Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 523-527
10. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638
11. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366-373
12. Girotra M, Rubin MR, Bilezikian JP 2006 The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7:113-121
13. Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E 2007 Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 22:64-71
14. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S 1997 Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970
15. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. J Bone Miner Res 16:925-931
16. Cosman F, Nieves JW, Lucky MM, Zion M, Woelfert L, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate alone for treatment. N Engl J Med 353:566-575
17. Iida-Klein A, Hughes C, Shen V, Moreno A, Lu SS, Dempster DW, Cosman F, Lindsay R 2006 Effects of cyclic vs. daily PTH regimens on bone strength in association with bone density, biochemical markers and bone structure in mice. J Bone Miner Res 21:274-282
18. Iida-Klein A, Lu SS, Dempster DW, Cosman F, Lindsay R 2007 Effects of cyclic vs. daily PTH on murine bone structure and cellular activity. Bone 40:391-398
19. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
20. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
21. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide onBMDafter treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
22. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH(1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
23. Gasser JA, Kneissel M, Thomsen JS, Mosedilde L 2000 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53-56
24. Li M, Jiao J, Meng XW, Xing XP, Xia WB, Zhou XY, Liu HC, Jiang Y, Wang O, Hu YY, Zhan ZW 2005 Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats. Zhonghua Yi Xue Za Zhi 85:335-338
25. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone( 1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008-2015
26. Pettway GJ, Meganck JA, Wei CL, Goldstein SA, McCauley, LK 2006 Anabolic actions of PTH in bone: role of osteoblast proliferation, differentiation, and combinatorial treatment with bisphosphonates. J Bone Miner Res 21(Suppl 1):S114
27. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves J, Lindsay R 2003 Precision, accuracy, and reproducibility of dual x-ray absorptiometry measurements in mice in vivo. J Clin Densitom 6:25-33
28. Iida-Klein A, Zhou H, Lu SS, Levine L, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of human parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816
29. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, Lindsay R 2005 Short-term continuous infusion of human parathyroid 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-557
30. Samadfam R, Xia Q, Goltzman D 2006 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63
31. Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, Sunn KL, Morrison NA, Walsh WR, Eisman JA 2000 Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 14:1908-1916
32. Iwata K, Li J, Follet H, Phipps RJ, Burr DB 2006 Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39:1053-1058
33. Allen MR, Follet H, Khurana M, Sato M, Burr DB 2006 Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 79:255-261
34. Bare S, Recker S, Recker R, Kimmel D 2005 Bone formation in the periosteal, endocortical, and trabecular envelopes of the ilium of adult women. J Bone Miner Res 20(Suppl 1):S274
35. Ma YL, Zeng Q, Donley DW, Ste-Marie L, Gallagher JC, Dalsky GP, Marcus R Eriksen EF 2006 Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864
36. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L 1999 Effects of treatment for 6 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25:301-309
37. Reeves J, Davies UM, Hesp R, McNally E, Katz D 1990 Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. Br Med J 301:314-318
38. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman A 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502
39. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082
40. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM 2006 Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887
41. Borg U Compressive strength of fiber composite with porosity. Proc 21st International Congress of Theoretical and Applied Mechanics, Warsaw, Poland, August 15-21, 2004 (Abstract SM13L-12214)
42. Aultman CD, Drake JD, Callaghan JP, McGill SM 2004 The effect of static torsion on the compressive strength of the spine: an in vitro analysis using a porcine spine model. Spine 29: E304-E309
43. Bono CM, Einhorn TA 2005 Overview of osteoporosis: pathophysiology and determinants of bone strength. In: Aebi M, Gunzburg R, Szpalski MP, eds. The aging spine. Heidelberg: Springer-Berlin; 8-14
44. Samadfam R, Xia Q, Golzman D 2007 Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787
45. Yates AJP, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR 1988 Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro rodents. J Clin Invest 88:932-938
46. Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM 1996 Sequential effects of chronic human PTH (1- 84) treatment of estrogen deficiency osteopenia in the rat. J Bone Miner Res 11:430-439